Myriad Genetics Raises 2026 Revenue Outlook Midpoint to $785 Million
Photo: TokenPost
Myriad Genetics raised the midpoint of its 2026 revenue outlook to $785 million, setting a range of $780 million to $790 million as higher revenue per test partly offsets expected Prenatal Health softness. Myriad management attributed reimbursement pressure to increased zero-pay outcomes and denials, rather than lower contract rates or changes in medical policy. The company identified process improvements, AI-enabled workflows and payer-specific market access efforts as ways to address the pressure. The outlook update follows Myriad’s agreement to sell its Prenatal Health testing business to Labcorp .
Source: TokenPost
